Abstract:Background: : Depression has recently been referred to as a neuroimmune disease because it is characterized by inflammatory changes in the cerebral cortex and hippocampus. Studies have demonstrated that microglial activation plays a crucial role in releasing inflammatory cytokines in the central nervous system (CNS), thereby contributing to depression, the mechanism underlying which remains unclear. Methods: : First, we examined microglial activation and inflammatory changes in C57BL/6 male mice injected with lipopolysaccharide (LPS; 1 mg/kg), which leads to depressive behaviors in mice that were attenuated by the antidepressant clomipramine. Second, we utilized a BV2 cell line and primary microglial cultures to determine the inflammatory response in vitro, and the effects of clomipramine exerted on the inflammatory response using real-time polymerase chain reaction and ELISA. Third, we utilized NLRP3 (NOD-like receptor protein 3) knockout (KO) mice to prove that NLRP3 is involved in the effects of clomipramine. Results: : The results showed that LPS injection induced depressive-like behaviors in mice, as assessed using several behavioral tests including body weight, and forced swimming and tail suspension tests. The LPS-induced expression of interleukin-lbeta (IL-1 beta), IL-6, and tumor necrosis factor alpha could be downregulated by clomipramine pre-treatment both in vivo and in vitro. The inhibitory effect of clomipramine on the LPS-induced increase in cytokines was found at both the protein and gene levels. Clomipramine significantly reduced the LPS-induced increase in NLRP3 gene expression in BV2 cells. Furthermore, we utilized NLRP3 KO mice to explore whether NLPP3 was involved in this process and found that clomipramine treatment inhibits the LPS-induced increased expression of IL-1 beta. Conclusion: : These results imply that clomipramine could attenuate depressive behaviors and neuroinflammation induced by LPS via partial regulation of NLRP3.

Microglial NLRP3 inflammasome-mediated neuroinflammation and therapeutic strategies in depression

The NLRP3 inflammasome in depression: Potential mechanisms and therapies

Microglia Sing the Prelude of Neuroinflammation-Associated Depression

Targeting NLRP3 Inflammasome in Translational Treatment of Nervous System Diseases: An Update

NLRP3 inflammatory pathway. Can we unlock depression?

Microglial NLRP3 Inflammasome Activates Neurotoxic Astrocytes in Depression-Like Mice

Regulation of indoleamine 2, 3-dioxygenase in hippocampal microglia by NLRP3 inflammasome in lipopolysaccharide-induced depressive-like behaviors

Microglial forkhead box O3a deficiency attenuates LPS-induced neuro-inflammation and depressive-like behaviour through regulating the expression of peroxisome proliferator-activated receptor-γ

Tert-Butylhydroquinone Prevents Neuroinflammation and Relieves Depression Via Regulation of NLRP3 Signaling in Mice

Microglial Glutaminase 1 Deficiency Mitigates Neuroinflammation Associated Depression.

Common Cellular and Molecular Mechanisms and Interactions Between Microglial Activation and Aberrant Neuroplasticity in Depression

Microglial NLRP3 Inflammasome Activation Mediates IL-1β-related Inflammation in Prefrontal Cortex of Depressive Rats

Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases

Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression

Inhibition of Microglial NLRP3 with MCC950 Attenuates Microglial Morphology and NLRP3/Caspase-1/IL-1β Signaling In Stress-induced Mice

Involvement of the Microglial NLRP3 Inflammasome in the Anti-Inflammatory Effect of the Antidepressant Clomipramine

Targeting Autophagy to Counteract Neuroinflammation: A Novel Antidepressant Strategy

NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies

Neuroinflammation and depression: A review

The Potential of NLRP3 Inflammasome As a Therapeutic Target in Neurological Diseases.

The Significance of NLRP Inflammasome in Neuropsychiatric Disorders